^
Association details:
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Title:

Health Canada Grants Marketing Authorization for Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Published date:
08/24/2021
Excerpt:
MorphoSys AG: today announced that Health Canada has granted Incyte, its development and commercialization partner for tafasitamab, a Notice of Compliance with conditions for Minjuvi(R) (tafasitamab), a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)...
Evidence Level:
Sensitive: A1 - Approval
Source:
Published date:
07/31/2020
Excerpt:
MONJUVI is a CD19-directed cytolytic antibody indicated in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).
Evidence Level:
Sensitive: A2 - Guideline
Title:

MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory DLBCL

Published date:
08/26/2021
Excerpt:
MorphoSys and Incyte Announce the European Commission Approval of Minjuvi(R) (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma.
Evidence Level:
Sensitive: A2 - Guideline
Source:
Published date:
08/13/2020
Excerpt:
Diffuse Large B-Cell Lymphoma…Other recommended regimen, "Tafasitamab + lenalidomide" was added as a category 2A recommendation.